Literature DB >> 20706850

Self-reported fatigue: one dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy--Fatigue (FACIT-F) questionnaire.

David Cella1, Jin-Shei Lai, Arthur Stone.   

Abstract

Across two general population (total n=1,878) and two cancer (total n=3,140) samples, we evaluated the dimensionality of self-reported fatigue as measured by the Functional Assessment of Chronic Illness Therapy--Fatigue (FACIT-F) instrument. After evaluating dimensionality of the FACIT-F, we compared the conceptually distinct fatigue experience versus fatigue impact scores in each sample. Confirmatory factor analysis of the 13-item scale showed very good fit to a single dimension ("unidimensional") model for each sample (comparative fit index range=0.92-0.97). Using a bifactor model to compare the loading of each item with the general fatigue factor versus the identified sub-domain (experience or impact), we found the item-general loading to be higher than that of the item-sub-domain factor in 52 of 52 comparisons (13 items; four samples). When scored separately, experience and impact scores were correlated highly (range=0.80-0.88), yet their difference relative to one another was significant (p<0.001). Consistently across samples, experience scores were systematically higher (more endorsement) than impact scores, by a margin of 0.21-0.46 SD units. This suggests that the fatigue experience and the impact of fatigue upon function are reported along a single dimensional continuum, but that experience is more likely than impact upon function to be endorsed at lower levels of fatigue. Fatigue as an outcome or trial endpoint can be expressed as a single number, and the experience of the symptom is more likely to be endorsed at mild levels of fatigue, presumably before the symptom exerts an adverse impact upon function.

Entities:  

Mesh:

Year:  2010        PMID: 20706850     DOI: 10.1007/s00520-010-0971-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

1.  A Comparison of Bifactor and Second-Order Models of Quality of Life.

Authors:  Fang Fang Chen; Stephen G West; Karen H Sousa
Journal:  Multivariate Behav Res       Date:  2006-06-01       Impact factor: 5.923

2.  Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS).

Authors:  Bryce B Reeve; Ron D Hays; Jakob B Bjorner; Karon F Cook; Paul K Crane; Jeanne A Teresi; David Thissen; Dennis A Revicki; David J Weiss; Ronald K Hambleton; Honghu Liu; Richard Gershon; Steven P Reise; Jin-shei Lai; David Cella
Journal:  Med Care       Date:  2007-05       Impact factor: 2.983

3.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.

Authors:  David Cella; Susan Yount; Mark Sorensen; Elliot Chartash; Nishan Sengupta; James Grober
Journal:  J Rheumatol       Date:  2005-05       Impact factor: 4.666

4.  The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment.

Authors:  David Cella; Richard Gershon; Jin-Shei Lai; Seung Choi
Journal:  Qual Life Res       Date:  2007-03-31       Impact factor: 4.147

5.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

Authors:  S B Yellen; D F Cella; K Webster; C Blendowski; E Kaplan
Journal:  J Pain Symptom Manage       Date:  1997-02       Impact factor: 3.612

6.  Fatigue in cancer patients compared with fatigue in the general United States population.

Authors:  David Cella; Jin-Shei Lai; Chih-Hung Chang; Amy Peterman; Mitchell Slavin
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

7.  Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue.

Authors:  Jin-Shei Lai; Paul K Crane; David Cella
Journal:  Qual Life Res       Date:  2006-09-25       Impact factor: 4.147

8.  Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

Authors:  G D Demetri; M Kris; J Wade; L Degos; D Cella
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

9.  The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years.

Authors:  David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose
Journal:  Med Care       Date:  2007-05       Impact factor: 2.983

10.  Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.

Authors:  David Cella; Martin J Zagari; Christina Vandoros; Dennis D Gagnon; Hans-Jürgen Hurtz; Johan W R Nortier
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

  10 in total
  36 in total

1.  Metabolic Rate and Perceived Exertion of Walking in Older Adults With Idiopathic Chronic Fatigue.

Authors:  Vincenzo Valiani; Duane B Corbett; Jeffrey D Knaggs; Todd M Manini
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-06-06       Impact factor: 6.053

2.  Energy, fatigue, or both? A bifactor modeling approach to the conceptualization and measurement of vitality.

Authors:  Nina Deng; Rick Guyer; John E Ware
Journal:  Qual Life Res       Date:  2014-11-02       Impact factor: 4.147

3.  Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale.

Authors:  Zeeshan Butt; Jin-Shei Lai; Deepa Rao; Allen W Heinemann; Alex Bill; David Cella
Journal:  J Psychosom Res       Date:  2012-11-15       Impact factor: 3.006

4.  Development and psychometric properties of the PROMIS(®) pediatric fatigue item banks.

Authors:  Jin-Shei Lai; Brian D Stucky; David Thissen; James W Varni; Esi Morgan DeWitt; Debra E Irwin; Karin B Yeatts; Darren A DeWalt
Journal:  Qual Life Res       Date:  2013-02-02       Impact factor: 4.147

5.  A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission.

Authors:  M Jennifer Cheng; B Douglas Smith; Christopher S Hourigan; Ivana Gojo; Keith W Pratz; Amanda L Blackford; Ambereen K Mehta; Thomas J Smith
Journal:  J Palliat Med       Date:  2017-05-24       Impact factor: 2.947

6.  The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Frasure; Deborah K Armstrong; Lari B Wenzel
Journal:  Gynecol Oncol       Date:  2011-11-23       Impact factor: 5.482

7.  Exercise and Fatigue in Adolescent and Young Adult Survivors of Hodgkin Lymphoma: A Report from the Children's Oncology Group.

Authors:  Catherine Fiona Macpherson; Mary C Hooke; Debra L Friedman; Kristin Campbell; Janice Withycombe; Cindy L Schwartz; Kara Kelly; Jane Meza
Journal:  J Adolesc Young Adult Oncol       Date:  2015-09       Impact factor: 2.223

8.  The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis.

Authors:  Richard Charles John Campbell; Michael Batley; Anthony Hammond; Fowzia Ibrahim; Gabrielle Kingsley; David L Scott
Journal:  Clin Rheumatol       Date:  2011-11-29       Impact factor: 2.980

9.  Fatigue in the general population: German normative values of the EORTC QLQ-FA12.

Authors:  Andreas Hinz; Joachim Weis; Elmar Brähler; Anja Mehnert
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

10.  Design of the Blood Pressure Goals in Dialysis pilot study.

Authors:  Ambreen Gul; Dana Miskulin; Jennifer Gassman; Antonia Harford; Bruce Horowitz; Joline Chen; Susan Paine; Edward Bedrick; John W Kusek; Mark Unruh; Philip Zager
Journal:  Am J Med Sci       Date:  2014-02       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.